In a significant advancement for aesthetic treatments, the U.S. Food and Drug Administration (FDA) has approved BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement of moderate to severe vertical bands connecting the jaw and neck, commonly known as platysma bands, in adults. This approval marks the first time an aesthetic neurotoxin has been authorized to address this area, expanding BOTOX® Cosmetic’s indications beyond the face to include the neck.
Understanding Platysma Bands
The platysma is a thin, superficial muscle that covers the neck and extends over the lower face. Over time, factors such as aging and lifestyle can lead to increased muscle activity, resulting in the appearance of vertical bands on the neck. These bands can contribute to a less defined jawline and are a common aesthetic concern among individuals seeking a more youthful neck appearance.
Clinical Insights and Treatment Protocol
In clinical studies, BOTOX® Cosmetic demonstrated significant improvements in the appearance of platysma bands. Patients received injections along the jawline and vertical bands with doses of 26, 31, or 36 units, depending on the severity of their condition. The treatment works by temporarily reducing the underlying muscle activity, leading to a smoother and more defined neck and jawline.
A majority of patients reported satisfaction with their neck and jawline definition 14 days after treatment, highlighting the procedure’s effectiveness. This minimally invasive approach offers a nonsurgical alternative for individuals seeking to enhance their neck aesthetics without undergoing more invasive procedures.
Implications for Aesthetic Practice
For aesthetic practitioners, this approval provides a new tool to address a previously challenging area. By incorporating BOTOX® Cosmetic for platysma bands into their practice, providers can offer patients a comprehensive treatment plan that addresses both facial and neck concerns. This development underscores the importance of staying informed about evolving treatment options to meet patient needs effectively.
Conclusion
The FDA’s approval of BOTOX® Cosmetic for the treatment of platysma bands represents a significant milestone in aesthetic medicine. It offers patients a new, minimally invasive option to improve the appearance of their neck and jawline, enhancing overall facial aesthetics. As the first product approved for this indication, BOTOX® Cosmetic continues to lead in expanding the possibilities of non-surgical aesthetic treatments.
Contact us to schedule your Botox appointment today, and let's talk about including this innovative new treatment area!
